Ebola Contracts Worth $2 Billion Could Benefit Drugmakers
This article is for subscribers only.
Drugmakers including Mapp Biopharmaceutical Inc., Johnson & Johnson and Emergent Biosolutions Inc. are among companies standing to gain from what may be $2 billion in U.S. contracts related to Ebola.
President Barack Obama asked Congress last week for $6.2 billion in emergency funding to stop the spread of the virus that has killed more than 4,800 people in West Africa. The request is heavily focused on health needs as opposed to prior funding that was largely centered on defense contracts, Brian Friel, a Bloomberg Intelligence contracts analyst, said.